@article{20b83545959f41d89314a8813ffec2cd,
title = "Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV",
abstract = "The first long-acting formulations of HIV drugs are undergoing regulatory review for use in maintenance of viral suppression in people with HIV. Although these novel drug formulations could contribute greatly to HIV treatment and prevention efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact, particularly in populations with high burdens of both HIV and HBV. An urgent need for greater investment in research and development of long-acting drugs with dual activity against HIV and HBV exists. Access to long-acting HIV drug formulations with dual activity against HBV would be transformative and have a great impact on efforts to prevent, treat, and eradicate both of these important global epidemics.",
author = "Bollinger, {Robert C.} and Thio, {Chloe L.} and Sulkowski, {Mark S.} and Jane McKenzie-White and Thomas, {David L.} and Charles Flexner",
note = "Funding Information: RCB reports grants from the US National Institutes of Health (NIH), during the conduct of the study, and personal fees from Merck & Co, outside the submitted work. CLT reports grants from NIH during the conduct of the study, and grants from Sanofi outside the submitted work. MSS reports grants and personal fees from Gilead, personal fees from Arbutus, and grants from Assembly Bioscience, during the conduct of the study. CF reports grants from Gilead Sciences, personal fees from Cipla Pharmaceuticals, Merck Laboratories, Mylan Pharmaceuticals, Janssen Pharmaceuticals, and ViiV Healthcare, outside the submitted work. In addition, CF has a patent for semi-solid prodrug nanoparticles pending. JM and DLT declare no competing interests. Funding Information: We thank the following individuals for their valuable input and opinions about this manuscript: Ashwin Balagopal, Chris Hoffman, Charles Holmes, Mina Hosseinipour, Leah M Johnson, and Ariane van der Straten. Support for this work, in part, is from the Long Acting/Extended Release Research Resource Program funded by the US National Institute of Allergy and Infectious Diseases (Grant R24 AI-118397), from the US National Institute of Drug Abuse (Grant R37DA013806), and from the Johns Hopkins University Center for AIDS Research (Grand P30AI094189), funded by multiple US National Institutes of Health Institutes and Centers. All content is solely our own responsibility and does not necessarily represent the official views of the US National Institutes of Health. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2020",
month = jun,
doi = "10.1016/S2352-3018(19)30342-X",
language = "English (US)",
volume = "7",
pages = "e443--e448",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",
number = "6",
}